Variables | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
HR | 95%CI | P–value | HR | 95%CI | P–value | |
Age | ||||||
<60 | reference | |||||
60–70 | 0.99 | 0.74 – 1.35 | 0.998 | 1.07 | 0.77 – 1.50 | 0.674 |
>70 | 0.99 | 0.70 – 1.39 | 0.936 | 1.08 | 0.73 – 1.59 | 0.710 |
Sex | ||||||
F | reference | |||||
M | 0.92 | 0.71 – 1.19 | 0.517 | 0.96 | 0.71 – 1.28 | 0.766 |
ECOG PS | ||||||
0 | reference | |||||
1 | 1.54 | 1.16 – 2.04 | 0.003 | 1.43 | 1.03 – 1.93 | 0.033 |
2 or more | 2.22 | 1.30 – 3.79 | 0.003 | 2.52 | 1.34 – 4.71 | 0.004 |
Body mass index | ||||||
<22 | reference | |||||
≥22 | 1.01 | 0.77 – 1.30 | 0.969 | 0.98 | 0.73 – 1.31 | 0.880 |
Tumor resection | ||||||
no | reference | |||||
yes | 0.73 | 0.50 – 1.07 | 0.103 | 0.71 | 0.45 – 1.12 | 0.142 |
Pancreatic tumor location | ||||||
Head | reference | |||||
Body | 1.04 | 0.78 – 1.39 | 0.800 | 0.89 | 0.63 – 1.25 | 0.496 |
Tail | 1.14 | 0.81 – 1.61 | 0.461 | 0.72 | 0.47 – 1.10 | 0.133 |
Tumor size | ||||||
<20 | reference | |||||
20 – 40 | 0.99 | 0.67 – 1.47 | 0.979 | 0.94 | 0.60 – 1.47 | 0.775 |
>40 | 1.39 | 0.91 – 2.11 | 0.125 | 0.88 | 0.54 – 1.43 | 0.605 |
Histology | ||||||
Adenocarcinoma | reference | |||||
Others | 1.09 | 0.75 – 1.56 | 0.656 | 1.26 | 0.83 – 1.90 | 0.280 |
Liver metastasis | ||||||
No | reference | |||||
Yes | 2.08 | 1.61 – 2.69 | < 0.001 | 1.85 | 1.26 – 2.73 | 0.002 |
Peritoneal metastasis | ||||||
No | reference | |||||
Yes | 0.95 | 0.68 – 1.31 | 0.742 | 0.91 | 0.57 – 1.44 | 0.674 |
Lung metastasis | ||||||
No | reference | |||||
Yes | 1.39 | 0.95 – 1.31 | 0.09 | 1.40 | 0.86 – 2.29 | 0.176 |
Number of metastasis | ||||||
0 or 1 | reference | |||||
2 or more | 1.59 | 1.21 – 2.09 | < 0.001 | 1.17 | 0.80 – 1.71 | 0.422 |
Ascites | ||||||
No | reference | |||||
Yes | 1.52 | 1.12 – 2.05 | 0.007 | 1.37 | 0.93 – 2.00 | 0.112 |
Albumin (g/dL), n (%) | ||||||
>4 | reference | |||||
3 – 4 | 0.82 | 0.54 – 1.24 | 0.349 | 1.45 | 0.88 – 2.37 | 0.144 |
<3 | 0.56 | 0.36 – 0.88 | 0.012 | 1.29 | 0.72 – 2.27 | 0.399 |
LDH (U/L), n (%) | ||||||
<240 | reference | |||||
240 – 360 | 1.91 | 1.32 – 2.77 | < 0.001 | 1.51 | 0.97 – 2.33 | 0.065 |
>360 | 2.90 | 1.36 – 6.19 | 0.006 | 2.88 | 1.35 – 6.82 | 0.007 |
CRP (mg/dL), n (%) | ||||||
<0.3 | reference | |||||
0.3–3.0 | 1.45 | 1.09 – 1.92 | 0.010 | 1.12 | 0.81 – 1.55 | 0.503 |
>3.0 | 3.04 | 2.09 – 4.43 | < 0.001 | 2.04 | 1.23 – 3.36 | 0.005 |
CA19–9 (U/mL), n (%) | ||||||
<37 | reference | |||||
37 – 370 | 1.24 | 0.84 – 1.84 | 0.285 | 1.18 | 0.77 – 1.80 | 0.441 |
>370 | 1.91 | 1.36 – 2.68 | < 0.001 | 1.45 | 1.01 – 2.07 | 0.043 |
AJCC TNM stage, n (%) | ||||||
III | reference | |||||
IV | 1.73 | 1.24 – 2.44 | 0.001 | 1.14 | 0.70 – 1.86 | 0.606 |
First line regimen, n (%) | ||||||
FFX | reference | |||||
GnP | 0.86 | 0.66 – 1.11 | 0.249 | 0.99 | 0.72 – 1.36 | 0.942 |